Skip to content

EV / sales at other companies

Baxter International logo
Baxter InternationalBAX
0.6×-0.8×
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
5.1×-0.9×
ADMA Biologics logo
ADMA BiologicsADMA
4.3×-5.8×
Medpace Holdings, Inc. logo
Medpace Holdings, Inc.MEDP
4.9×+0.7×
Biodesix, Inc. logo
Biodesix, Inc.BDSX
+0.1×
ClearPoint Neuro logo
ClearPoint NeuroCLPT
7.3×-2.6×

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Calculated from Lifecore Biomedical, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s EV / sales?
Lifecore Biomedical, Inc. (LFCR) reported EV / sales of 2× in Q1 2025.
How has Lifecore Biomedical, Inc.'s EV / sales changed year-over-year?
Lifecore Biomedical, Inc.'s EV / sales decreased by 6.7% year-over-year, from 2.2× to 2×.
What is the long-term trend for Lifecore Biomedical, Inc.'s EV / sales?
Over 4 years (2021 to 2025), Lifecore Biomedical, Inc.'s EV / sales has grown at a -18.3% compound annual growth rate (CAGR), from 4.6× to 2×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.